Uppsala, Sweden – Strike Pharma has received funding from the BIO-X Accelerate program. The project is financed by the European Regional Development Fund (ERDF) through The Swedish Agency for Economic and Regional Growth via STUNS program BIO-X Accelerate.“With support from this call that focused in on IMPACT, we will pursue our work on the Adaptable Drug Affinity Conjugate (ADAC) technology, to provide a technology for targeted delivery of oligonucleotide-based therapies” says Sara Mangsbo, Chief Scientific Officer at Strike Pharma.



About Strike Pharma (www.strikepharma.com)

Headquartered in Uppsala, Sweden, Strike Pharma is using the company’s proprietary Adaptable Drug Affinity Conjugate (ADAC) technology to take precision medicine to a new level, enabling development of truly individualized immunotherapeutic treatments based on the genetic profile of each patient’s tumor. Such highly targeted treatment offers the potential to not only increase therapeutic efficacy, but also to reduce dosage levels thereby minimizing the risk of side effects.

Today, Strike Pharma’s development program is focused on selection of novel, clinically-relevant candidates for use as immunotherapeutic treatment of solid tumors. However, the company is confident that the ADAC technology platform has the potential to facilitate development of many other antibody-based therapeutics and that this novel approach will have a significant impact across a wide variety of disease indications within the rapidly developing field of personalized medicine.

Strike Pharma was founded in 2020 with the aim of commercializing ADAC technology. Investors include Eir Ventures, Flerie Invest, Uppsala University Invest, Almi Invest, SLU Invest and Monesi Förvaltnings.


Mårten Winge CEO

+46 (0) 70 657 59 27

[email protected]

About BIO-X

BIO-X Accelerate is a program with the goal of accelerating development of innovation in the health and/or life science industry. The program uses an industrial approach to support life science-related projects that could fulfill well-defined needs and create IMPACT in healthcare, industry and society. Selected companies receive funding for their projects as well as continued support and access to experts within the BIO-X network.

BIO-X Accelerate with the theme IMPACT is a project by STUNS with strategic partners UIC, Connect Uppsala, Create Business Incubator, Lead (Business Incubator), Inkubera and supporting partners Linköping University Innovation, Uppsala University and Örebro University Holding.

The project is financed by European Regional Development Fund (ERDF) through The Swedish Agency for Economic and Regional Growth via STUNS